In its biggest investment so far, CordenPharma is earmarking €900 million ($982 million) over the next three years to expand its peptide platform capacity in the US and Europe to meet rising GLP-1 manufacturing demand.
The Swiss CDMO will build a third facility at its only North American site in Boulder, CO, as well as add large-scale peptide manufacturing lines at one of two of its existing facilities in the same site. Its existing facilities in Colorado currently manufacture peptides, oligonucleotides, lipids and APIs for clinical and commercial use.
CordenPharma will also build a new site from scratch in “the heart of Europe” — without disclosing specifically where it would be — and will be used for large-scale clinical and commercial peptide manufacturing for GLP-1 drugs. The company presently has a total of 10 manufacturing sites in Europe, plus the site in Colorado.
The expansion is a result of increasing…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
